Publicacións en colaboración con investigadores/as de Complejo Asistencial de Ávila (10)

2022

  1. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

2021

  1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  2. Effect of the type of specialized nutrition support on the course of the patient with amyotrophic lateral sclerosis (ALS). Interhospital registry SCLEDyN

    Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 10, pp. 699-707

2020

  1. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2017

  1. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

  2. Prognostic accuracy of SIRS criteria, qSOFA score and GYM score for 30-day-mortality in older non-severely dependent infected patients attended in the emergency department

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 12, pp. 2361-2369

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

2014

  1. Guideline on management of solitary pulmonary nodule

    Archivos de Bronconeumologia, Vol. 50, Núm. 7, pp. 285-293

2012

  1. Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab

    Journal of Neuroimmunology, Vol. 243, Núm. 1-2, pp. 103-105